CD274 and neoplasm: Recent evidence suggests that the bioengineered human PEGylated arginase 1 (AEB1102) exerts additive anti-tumor effects when combined to anti-PD-1 or anti-PD-L1 in melanoma, small cell lung cancer (SCLC), and sarcoma patient-derived xenografts (183, 184).